Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02664766
Other study ID # UThessaly 2
Secondary ID
Status Completed
Phase N/A
First received January 18, 2016
Last updated January 26, 2016
Start date January 2014
Est. completion date June 2015

Study information

Verified date January 2016
Source University of Thessaly
Contact n/a
Is FDA regulated No
Health authority Greece: Ethics Committee
Study type Interventional

Clinical Trial Summary

The purpose of this research is to examine the effects of long-term aerobic exercise of moderate intensity on psychological, physiological, biochemical, physiological and alcohol-related parameters in heavy drinkers, in order to investigate possible biochemical mechanisms by which exercise may be a healthy alternative to alcohol abuse.


Description:

The mechanism of incentives that lead people to unhealthy habits such as excessive alcohol consumption is not only social, personal, and psychological, but also associated with neurochemical and neurobiological mechanisms.

Several programs have been developed to stop excessive drinking, but the success rates are small, while the relapse rates are very high, reaching up to 90%. Although there is some evidence for the beneficial effects of exercise on alcohol use disorders, research is limited. The present study investigates whether exercise can act as adjunct therapy for alcohol abuse cessation.

One of the basic assumptions is that the appropriate form of exercise in alcoholics will contribute to the secretion of beta-endorphin, which in combination with psychological pleasure, vitality, change of mood, reduced stress, increased confidence, and the shift of attention will help people to follow healthy lifestyles and abhor alcohol.

The research project is divided in three phases. In the first phase, the effect of acute exercise in critical psychological, physiological, biochemical and alcohol-related parameters associated with excessive alcohol consumption will be examined. In the second phase (current study), a long-term exercise program in conjunction with psychological support strategies aimed at alcohol abuse cessation will be developed, implemented and evaluated. Finally, in the third phase, based on the results of the previous phases, awareness programs in adolescent and adult populations will be designed and implemented as well as the dissemination of results and evaluation of the project will take place.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date June 2015
Est. primary completion date July 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Men drinking >14 drinks/week or >4 drinks/occasion; Women drinking >7 drinks/week or >4 drinks/occasion (1 drink = 14 grams of pure alcohol; definition of the NIAAA for drinking at low risk for developing an AUD; NIAAA, 2014)

- Individuals drinking 5 or more drinks on the same occasion on each of 5 or more days in the past 30 days (1 drink = 14 grams of pure alcohol; definition of the Substance Abuse and Mental Health Services Administration for heavy drinking; NIAAA, 2014) Alcohol Use Disorders Identification Test (AUDIT) score>8

Exclusion Criteria:

- Medical conditions or medication use that would preclude participation in aerobic exercise

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Behavioral:
Exercise training program
Supervised 8-week exercise training program. Aerobic exercise (walking, jogging) of increasing duration at 50-60% HRR, at least two sessions per week. Participants will be recording their daily alcohol consumption. Participants will also undergo three trials of acute exercise (before, at the 4th week and at the 8th week of exercise training) in order to investigate whether exercise training can lead to changes in acute responses to exercise. Each trial involves 30 min of exercise on a cycle ergometer at 50-60% HRR.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
University of Thessaly European Social Fund

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in alcohol consumption (grams of alcohol consumed weekly) Self-recorded At baseline and at 4th week of control condition; at baseline (before intervention), at 4th week and at 8th week of intervention No
Primary Changes in Beta-endorphin levels Measured by radioimmunoassay (RIA) At baseline and at 4th week of control condition; at baseline (before intervention), at 4th week and at 8th week of intervention No
Secondary Urge to drink According to questionnaire At baseline and at 4th week of control condition; at baseline (before intervention), at 4th week and at 8th week of intervention No
Secondary Cortisol Measured by radioimmunoassay (RIA) At baseline and at 4th week of control condition; at baseline (before intervention), at 4th week and at 8th week of intervention No
Secondary Adrenocorticotrophic hormone (ACTH) Measured by radioimmunoassay (RIA) At baseline and at 4th week of control condition; at baseline (before intervention), at 4th week and at 8th week of intervention No
Secondary Catecholamines (epinephrine, norepinephrine, dopamine) Measured by radioimmunoassay (RIA) At baseline and at 4th week of control condition; at baseline (before intervention), at 4th week and at 8th week of intervention No
Secondary C-reactive protein (CRP) Semi-quantitative estimation with CRP Latex test kit At baseline and at 4th week of control condition; at baseline (before intervention), at 4th week and at 8th week of intervention No
Secondary Complete blood count Autoanalyzer Autoanalyzer Autoanalyzer At baseline and at 4th week of control condition; at baseline (before intervention), at 4th week and at 8th week of intervention No
Secondary Lactic acid Measured using photometry At baseline and at 4th week of control condition; at baseline (before intervention), at 4th week and at 8th week of intervention No
Secondary Erythrocyte sedimentation rate (ESR) Wintrobe Method At baseline and at 4th week of control condition; at baseline (before intervention), at 4th week and at 8th week of intervention No
Secondary ?-Glutamyltransferase (GGT) Measured with commercial kit At baseline and at 4th week of control condition; at baseline (before intervention), at 4th week and at 8th week of intervention No
Secondary Aspartate Aminotransferase (AST) Measured with commercial kit At baseline and at 4th week of control condition; at baseline (before intervention), at 4th week and at 8th week of intervention No
Secondary Alanine Aminotransferase (ALT) Measured with commercial kit At baseline and at 4th week of control condition; at baseline (before intervention), at 4th week and at 8th week of intervention No
Secondary Sit and reach flexibility test for the hamstrings muscles and lower back Each participant sits on the floor with legs stretched out straight ahead, reaches out and holds that position for at 1-2 seconds while the distance is recorded. At baseline and at 4th week of control condition; at baseline (before intervention), at 4th week and at 8th week of intervention No
Secondary Grip strength Handgrip strength test At baseline and at 4th week of control condition; at baseline (before intervention), at 4th week and at 8th week of intervention No
Secondary Number of push-ups performed in one minute At baseline and at 4th week of control condition; at baseline (before intervention), at 4th week and at 8th week of intervention No
Secondary Number of sit-ups performed until exhaustion At baseline and at 4th week of control condition; at baseline (before intervention), at 4th week and at 8th week of intervention No
See also
  Status Clinical Trial Phase
Recruiting NCT04788004 - Long-term Recovery: Longitudinal Study of Neuro-behavioral Markers of Recovery and Precipitants of Relapse
Recruiting NCT05684094 - Mechanisms of Risky Alcohol Use in Young Adults: Linking Sleep to Reward- and Stress-Related Brain Function N/A
Completed NCT03406039 - Testing the Efficacy of an Online Integrated Treatment for Comorbid Alcohol Misuse and Emotional Problems N/A
Completed NCT03573167 - Mobile Phone-Based Motivational Interviewing in Kenya N/A
Completed NCT04817410 - ED Initiated Oral Naltrexone for AUD Phase 1
Active, not recruiting NCT04267692 - Harm Reduction Talking Circles for American Indians and Alaska Natives With Alcohol Use Disorders N/A
Completed NCT03872128 - The Role of Neuroactive Steroids in Stress, Alcohol Craving and Alcohol Use in Alcohol Use Disorders Phase 1
Recruiting NCT06030154 - Amplification of Positivity for Alcohol Use N/A
Active, not recruiting NCT05419128 - Family-focused vs. Drinker-focused Smartphone Interventions to Reduce Drinking-related Consequences of COVID-19 N/A
Completed NCT04564807 - Testing an Online Insomnia Intervention N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT04203966 - Mental Health and Well-being of People Who Seek Help From Their Member of Parliament
Recruiting NCT05861843 - Craving Assessment in Patients With Alcohol Use Disorder Using Virtual Reality Exposure
Terminated NCT04404712 - FAAH Availability in Psychiatric Disorders: A PET Study Early Phase 1
Enrolling by invitation NCT04128761 - Decreasing the Temporal Window in Individuals With Alcohol Use Disorder N/A
Not yet recruiting NCT06337721 - Preventing Alcohol Use Disorders and Alcohol-Related Harms in Pacific Islander Young Adults N/A
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A
Enrolling by invitation NCT02544581 - Preliminary Analysis of the Soberlink Alcohol Breath Analyzer System's (SABA) Clinical Utility During Aftercare N/A
Completed NCT02511886 - A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder Phase 2
Active, not recruiting NCT02185131 - Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD. Phase 2